Dennis Slamon, M.D., Ph.D., director of clinical/translational research for the Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center, presented updated results of his groundbreaking work with trastuzumab, currently sold as Herceptin by Genentech-Roche. Slamon presented his study at the CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12, 2009. Immediately following this presentation, he took questions from registered media representatives. Listen to a recording of the briefing and read the press release
for more information.
* the mp3 of the teleconference (13.2 MB, 58 minutes and 04 seconds)
*On a PC, right mouse click on the "Download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.